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Novel Neurotechnologies: Intervening on the Brain 
By Graeme Laurie
The Nuffield Council on Bioethics has produced its latest report on the ethical, legal and social 
implications of novel neurotechnologies. This report is very timely because many of the 
technologies in question are on the cusp of moving from the research stage to the health 
context. They are important for a range of patients suffering from neurological conditions such 
as Parkinson’s Disease, Alzheimer’s, stroke, depression and OCD. Over 800,000 people 
suffer from dementia in the UK and 1 in 500 people have Parkinson’s Disease.
The Nuffield Council Working Party which produced the report, and which included 
involvement from MI’s Director, Graeme Laurie, seeks to strike a balance between the 
necessary caution required whenever science intervenes on the brain and the imperative to 
improve innovation, access and effective regulation of these technologies to help to ensure 
that the right treatments get to the right patients at the right time.
The technologies in question include:
• Deep Brain Stimulation (DBS): this is an invasive procedure requiring brain surgery 
to insert electrodes in specific regions of the brain in order to receive pulses of 
electric current from generators also inserted in the body (usually the chest). There 
is good evidence that DBS has helped thousands of patients suffering from 
Parkinson’s by reducing the tremors associated with the condition. However, there 
is a cost, including sleep disruption and increased anxiety for some patients. The 
Nuffield Report argues that we must learn from the experiences of patients who 
have used DBS to date to see whether and how it might be used for other 
conditions that include Alzheimer’s and even anorexia. We simply do not know 
enough at the moment about how these interventions work in practice. 
Accordingly, the Council recommends the establishment of publicly-available 
registers to capture and share patient and clinician experiences. It also 
recommends that patients being offered invasive procedures should receive 
independent counselling before they take part and this should include full 
information about likely benefits and risks.
• Brain-Computer Interfaces (BCIs): these technologies involve the placing of 
electrodes on the scalp (or occasionally in the brain) to record brain signals that 
can be translated to instructions that could allow patients to move artificial limbs or 
communicate better after a stroke. These technologies are still at the research 
stage but they have been picked up in some non-health contexts such as gaming 
and educational enhancement by companies suggesting that they can assist with 
learning and play. The problem is that we simply do not know enough about 
whether these devices work at all. The Council calls on the European Commission 
to regulate all non-therapeutic brain devices as if they were medical devices. This 
would allow proper oversight of market approval in the UK by the MHRA and would 
include capture of people’s experiences of using them in European health 
databases. The Council further recommends parents and teachers should received 
official advice on the effectiveness – or not – of devices that claim to enhance 
children’s learning.
• Neural Stem Cells: these very new methods involve the surgical injection of stem 
cells into parts of patients brains in an attempt to replace or regenerate brain 
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tissue. Only one study is currently being trialed in the UK. Early results are, 
however, promising. Safety is clearly paramount in this and all other cases 
involving these technologies. For stem cells, however, the real challenge is to 
smooth the regulatory pathway from research to bedside. These technologies are 
regulated in the same way as pharmaceuticals and in that context it can cost over 
$500 million dollars to get drugs to market. We do not currently know the costs of 
neural stem cell technologies but the regulatory system must do two things: (i) 
make research subject safety the top priority *while also* (ii) encouraging 
innovation in the field. The Nuffield Council welcomes recent initiatives between 
regulators both to work more closely together and to maintain effective dialogue 
with stem cell developers. More imaginative thinking is required to incentivise 
investors to commit to these developments without diluting effective scrutiny and 
patient safety.
The report is also concerned with excessive ‘hype’ around these new technologies. Headlines 
like ‘Paralysed man’s mind is “read”‘ are not only seriously inaccurate, but can also give rise to 
unnecessary fears or misinformation for patients deciding on whether novel 
neurotechnologies are for them. Accordingly, the Nuffield Council calls upon the media, press 
offices, research institutes, researchers and their funders to be more responsible in their 
communication about the reality and the limits of these technologies and offers clear 
guidelines on what responsible communication might look like. The overarching theme of this 
report is one of balance: there is considerable unmet need out there and we must proceed 
with caution. Equally, we required smarter regulation mechanisms that deliver both safety 
protection and effective treatments to the patient’s who need them.
Link to report: http://www.nuffieldbioethics.org/neurotechnology
This post was first published on 25 June 2013.
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